Posts tagged Biomedical
Kitware, Inc. Tapped National Alliance for Medical Image Computing for the further development of the toolkit of advanced biomedical imaging
0Clifton Park, NY (Vocus) 6 October 2010
Kitware, developers of open source solutions and cutting-edge research, today announced the renewal of a contract with the National Alliance for Medical Image Computing (NA-MIC), continues the development of NA-MIC-Kit, a high quality software for the resolution of medical image analysis and visualization challenges in biomedical research. In addition, Kitware of NA-MIC was commissioned to assist in the search for traumatic brain through the analysis of longitudinal MRI studies.
a national of seven Centers for Biomedical computer science (NCBC), NA-MICA? Focuses on the scientific advances in biomedical imaging, open-source resources to convert to develop advanced software tools. In 2004 Kitware of NA-MIC has been commissioned to develop the original kit, a scalable open-source software free of physicians and biomedical scientists to mine large amounts of image data and the use of advanced computing techniques, tools such as statistical analysis and longitudinal data to identify unique patients, and they relate to the patient population as a whole, this integrated approach in the form of personalized medicine is defined ????.?? ? s Kitware improvements? will also help the application of the instruments in the fields of cancer, heart disease, trauma and degenerative genetic disease research.
Under the new contract
Kitware is in control of engineering and service cores retain. The goal of basic engineering remain faithful to the original contract and continue the provision of software tools and software development processes focus on delivering innovative technologies for clinical research, support for other drivers and provide a community that promotes high quality software. However Kitware? S Kita improve focus? S to monitor maturation personalized medicine through patient data analysis and extend the capabilities of 3D Slicer Toolbox. Dr. Will Schroeder, President, CEO and co-founder of Kitware, again take the lead in the initiative.
core service, which are led by Kitware? Director of Medical Imaging, Dr. Stephen Aylward, is responsible for supporting the dissemination and training carrots in their efforts to learn the biomedical, teaching and cutting-edge biomedical research in the kit to help NA-MIC. Kitware will ensure that all support services via the Web in place for the smooth running of training and NA-MIC events research, which are oriented to building a base of active users for the NA-MIC Kit and feedback in person and online learning resources.
In addition, Dr. Aylward also the lead in the design of head injuries in the conduct of basic biological projects. Kitware will focus on the use of imaging biomarkers as surrogate endpoints in long-term success of treatment to assess, under the direction of Dr. Guido Gerig, University of California, Los Angeles. In particular, Kitware develop, refine and integrate interactive computer-based segmentation algorithms Dr. Gerig? S 3D Slicer for help in developing new techniques for analyzing a database of case studies with multimodal MRI / DTI imaging. This goes way beyond the traditional imaging methods produce.
longitudinal analysis is particularly important because they act in the patients as their own control group, long-term consequences of trauma and quantify response to treatment allowed if they are studied in different populations. This form of analysis will also help evaluate treatment options much faster than conventional methods.
About Kitware
Kitware, Inc. is a leader in the creation and support of free software and the state of the art and is one of the fastest growing software in the country. Kitware is using its open-source communities, and various advanced technical skills to provide customized solutions for a variety of complex technical problems.
Founded in 1998, Kitware? The team is known for their significant contributions to a variety of open-source software systems, including the Visualization Toolkit (VTK), Insight Segmentation and Registration Toolkit (ITK) rules and CMake ParaView.
Kitware has had an impact in areas such as visualization, data processing, medical imaging, a process of software quality, computer vision and computer. In Kitware? S worldwide customers and employees are a variety of academic research institutions, government institutions and private companies worldwide. Kitware products and services include software support, consulting, application development and training and productivity tools that take advantage of our open-source systems.
About the National Alliance for Medical Imaging Computing
Alliance for Medical Image Computing (NA-MIC) is a multi-institutional, multidisciplinary team of computer scientists, software engineers and medical researchers to develop the tools for analysis and visualization of medical image data. The center aims, infrastructure and environment for the development of computational algorithms and open source technologies offer, and monitor the training and dissemination of these tools in medical research.
>
clear = “all”
Treatment of heartburn
Ohio Third Frontier Commission awarded $ 14 million in grants for biomedical research
0Ohio Third Frontier Commission awards $14M in biomedical grants
Ohio Third Frontier commissioners made a slew of biomedical grants under two programs today. Recommended for more than $4.9 million under the Ohio Third Frontier Biomedical Program: – CardioX Corp., Dublin, in collaboration with Nottingham-Spirk Design Associates in Cleveland and QTest Labs in Columbus, was awarded $986,373 to finalize designs and clinical protocols for a new method [...]
Read more on MedCity News
Boston Biomedical to present updated Phase I study data of BBI608 cancer drug at 101st AACR
0Boston Biomedical to present updated Phase I study data of BBI608 cancer drug at 101st AACR
Researchers at Boston Biomedical, Inc., are working to develop a novel first-in-class cancer drug that works by targeting the stem like properties of some cancer cells, and so far, results of an ongoing Phase I clinical trial demonstrate early signs of a strong safety profile and clinical activity.
Read more on News-Medical-Net